Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update
Előd Ernő Nagy,1 Csilla Nagy-Finna,1,2 Horațiu Popoviciu,2 Béla Kovács1 1Department of Biochemistry and Environmental Chemistry, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu Mureș, Târgu Mureș, Romania; 2Department M4,...
Guardado en:
Autores principales: | Nagy EE, Nagy-Finna C, Popoviciu H, Kovács B |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/274438b71e2b49499af736e01e377ed4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas KM, et al.
Publicado: (2014) -
Is grand multiparity a risk factor for the development of postmenopausal osteoporosis?
por: Peker N, et al.
Publicado: (2018) -
Pharmacological treatment of osteoporosis in the oldest old
por: Vandenbroucke A, et al.
Publicado: (2017) -
Role of zoledronic acid in the prevention and treatment of osteoporosis
por: Räkel A, et al.
Publicado: (2011) -
Concentration of cytokines in patients with osteoarthritis of the knee and fibromyalgia
por: Imamura M, et al.
Publicado: (2014)